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MOLECULAR RELATIONSHIP BETWEEN PRIVATE
AND PUBLIC H-2 ANTIGENS AS DETERMINED BY
ANTIGEN REDISTRIBUTION METHOD*
By VERA HAUPTFELD AND JAN KLEIN
(From the Department of Microbiology, The University of Texas Southwestern Medical School,
Dallas, Texas 75235)
Classical H-2 antigens can be dividedinto two, not very sharply defined groups,
private and public . Private H-2 antigens (1) have a restricted strain distribution:
among inbred strains they are found in only one haplotype ofindependent origin ;
public H-2 antigens (2), on the other hand, are shared by at least two, and quite
often by a large number of unrelated haplotypes. Private H-2 antigens are
believed to be controlled by alleles of two loci at the opposite ends of the H-2
complex, the H-2K locus in the K region, and the H-2D locus in the D region . In
agreement with this belief, the antigens can be arranged in two series, where
members of each series are mutually exclusive (3). No such arrangement is
possible for the public H-2antigens and the nature ofthe genetic control ofthese
antigens has long been a matter of controversy.
According to the traditional interpretation of the H-2 complex (4), the public antigens
are controlled by separate regions located between the K and D regions within the
complex . According to the two-locus model (5), public H-2 antigens reside in the same
molecules as the private ones and are controlled either by the H-2K or H-2D loci, or both.
The two-locus model fits better the available data than the traditional multi-locus model
(6). Also, the former model is supported by the results of transplantation analysis
demonstrating that only the peripheral regions of the H-2 complex are involved in rapid
skin-graft rejection (7) . However, a formal proof that the serologically detectable public
H-2 antigens are coded for by the K and D regions has never been provided. As a matter of
fact, most recent developments (8, 9, cf. Discussion) suggest that an across the board
assignment of public antigens to K and D regions could not be justified. Despite these
developments, many investigators accept the two-locus model as an established fact and
rely on it in their interpretation of the H-2 system. At this stage it is, therefore, critical to
test whether the serologically detectable public H-2 antigens conform to the predictions of
the two-locus model .
We have recently developed a method that can be used to examine molecular
relationships among various cell membrane antigens. The method is based on the
observation that under certain circumstances, antigens coated with alloanti-
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tribute in the cell membrane in such a way that the cell becomes resistant to
subsequent exposure of the same alloantibodies and complement; however, the
cell remains sensitive to antibodies (and complement) directed against antigens
not physically associated with the coated antigens (10). Using this method, we
were able to demonstrate that private H-2 antigens controlled by the K region
redistribute independently of those controlled by the D region, and that H-2
antigens redistribute independently of la antigens and of membrane bound Ig
(l1). In this communication we extend these studies and examine the molecular
relationship between private and public H-2 antigens.
Materials and Methods
Mice.
￿
All mice were bred in our colony at the University of Texas Health Science Center.
Antisera. H-2 alloantisera used and the antibodies they contain are listed in Table I. The
K-series antisera were produced in our laboratory using an immunization regimen described
previously (12) . The D- and C-series antisera were produced at theJackson Laboratories,Bar Harbor,
VERA HAUPTFELD AND JAN KLEIN
TABLE I
Characteristics of H-2 Alloantisera Used in the Present Study
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K-series antisera were produced in this laboratory; D- and C-series were produced by Doctors M.
Cherry andG. D. Snell at theJacksonLaboratories undera contract through theNational Institutes
of Health; As-485 was kindly supplied to us by Dr. G. D. Snell.
Maine by Doctors Marianna Cherry and George D. Snell under a contract from the National
Institutes of Health. Specificity of all alloantisera was determined by testing them against a panelof
inbred strains and congenic lines representing major H-2 haplotypes. The goat antimouse Ig(K, 'Y)
xenoantiserum (GAMIG)' was a gift from Dr. Ellen S. Vitetta, of this department.
Cell Suspensions,
￿
Spleen was placed into a Petri dish containing Hanks' BSS and adhering fat
`Abbreviations used in this paper: ACT, ammonium chloride Tris; AMIRC, antibody-mediated
induction of resistance to cytotoxicity; As, antiserum; BSS, balanced salt solution; GAMIG, goat
antimouse Ig serum; NMS, normal mouse serum; PBS, phosphate-buffered solution.
Antiserum
no.
Recipient Donor
H-2
haplotype
combination
Antibodies
present
D-lb (C3H.SW x HTG)F, C3H-H-2° (blg)o2 1,32
K-302 (BIO.D2 x A)F, B10.A(2R) (dla)h2 2
K-304 (A.BY x B10.AKM)F, B10.A (b/m)a 4
K-46 (HTG x BIO.D2)F, C57BL/IOSn (g/d)b 5,33
K-35 C3H/HeJ C3H.R3 (k)r 6,18
D-8 (BIO x A.SW)F, B10.M (b/s)f 8,9,37
C-11A (B10.D2 x C3H.NB)F, LP.RIII (dlp)r 11,25
D-13 (B10 x LP.RIII)F, B10.A(5R) (blr)i5 4,13,41,42,43.44
K-26 (B10 x A)F, AQR (bla)y1 17
K-323 [B10.RIII (71NS) x DBA/2JF, B10.A (rld)a 23
K-325 (DBA/2 x B10.G)F, B10.RIII(71NS) (dlq)r 18,25
D-28 (A.CA x B10.BR)F, A.SW (flk)s 12,19,28,36,42
K-113 (B10 x C3H)F, B10.AKM (b/k)m 30
K-131 (A x B10.A)F, B10.D2 (a)d 31
As-485 [310 .A(2R) x C3H.SWJF, C3H/Sn (h2/b)k 32,45,47
K-30 (B10.D2 x A)F, HTI (d1a)i 33.39290
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tissue was removed. Theorgan wasthen fragmented with aspatula and cells released by teasing. The
suspension was flashed back and forth in a Pasteur pipette, large fragments were allowed to sediment
for 5 min in a test tube, and the supernate was transferred into another tube and centrifuged.
Erythrocytes were destroyed by washing the cells twice in ammonium chloride Tris (ACT), followed
by washing in HBSS. The cells were then counted and diluted to a required concentration. Thewhole
procedure, except for the ACT treatment, was carried out in the cold.
Antibody-Mediated Induction of Resistance to Cytotoxicity (AMIRC) Technique.
￿
Themethod of
AMIRC was described previously (11) . Briefly, spleen cells were suspended in Hanks' BSS and
divided into aliquots, each containing 5 x 108 cells. Thesuspensions were centrifuged, the supernates
removed, the cells resuspended in H-2alloantisera appropriately diluted in PBS andincubated for 2 h
on ice . After the incubation, the cells were washed twice in the cold with BSSand incubated for 1 hon
ice with GAMIG antiserum diluted in PBS. The cells were then washed twice in BSS, resuspended in
RPMI medium containing 10% heat-activated normal mouse serum (pool) and cycloheximide (50
kg/ml) to give afinal concentration of 2 x 108 cells/ml, and incubated for 1 hat 37°C. Thesuspension
was then cooled to 0°C, washed twice with BSS, and the incubation with the GAMIG serum was
repeated one more time. At the end of the second Ig treatment, the suspension was used without
washing in thecytotoxicity test which was performed at room temperature (except for the incubation
period with complement) .
Cytotoxicity Test. Susceptibility or resistance to cytotoxicity after antisera treatment was
determined by using the two-stage microcytotoxicity test of Amos and his co-workers (13), modified
as described previously (14). Live and dead cells were distinguished by using an inverted
phase-contrast microscope . Commercially available normal guinea pig serum (Grand Island
Biological Co., Grand Island, N.Y.), diluted 1:2 or 1 :4 was used as a source of complement.
Results
The most recent H-2 chart (6) lists 52 H-2 antigens. Of these, 18 are classified
as private and the remaining 34 as public . Of the public antigens, those with a
number lower than 33 have been known for some time and, consequently, are
better characterized than most of the newer H-2 antigens. For this reason, we
limited our study to the older antigens, namely to antigens H-2.1, 5, 6, 8, 11, 13,
25, and 28. In the following we shall deal with these antigens one by one.
H-2.1 .
￿
This is one of the most versatile antigens in the whole H-2 system.
Although H-2.1 antibodies cross-react with most unrelated H-2 haplotypes, the
H-2.1 antigen of any particular haplotype appears to be slightly different from
the H-2.1 antigen of another haplotype (15) . Although sites reacting with H-2.1
antibodies have been postulated on both K and D molecules, the primordial
H-2.1 site is believed to be controlled by the K region . The anti-H-2.1 serum
which we used (D-1b) was produced in such a way as to contain only H-2.1
antibodies reacting with the K site . When we applied this antiserum to
B10.A(H-2a) cells, we observed that redistribution of antigen H-2.1 was always
accompanied by redistribution of H-2.23, the private antigen controlled by the K
region of the H-2a haplotype (Table II). Similarly, redistribution of antigen
H-2.23 was always accompanied by redistribution of antigen H-2.1 . On the other
hand, antigen H-2.4, controlled by the D region of H-2a, redistributed independ-
ently of both H-2.1 and H-2.23. These results suggest that in the cell membrane
of H-2a mice, antigen H-2.1, as detected by antiserum D-1b, is physically
associated with the H-2K molecule .
H-2.5. This antigen has been genetically mapped in the K region but
according to the duplication model (16), a homologous genetic determinant is
located also in the D end. Our data (Table III) confirm this prediction of the
duplication model. The data show that in CBA/J (H-2k) cells, redistribution ofVARA HAUPTFELD AND JAN KLEIN
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TABLE II
Redistribution of Antigens H-2.1(D-Ib), H-2.4(K-304), and H-2.23(K-323) AfterPretreat-
ment of BIO.A(H-2a) Spleen Cells with H-2 Alloantisera and GAMIG
* As = H-2 alloantiserum; dilution of antiserum in parentheses; n = undiluted.
$Measured in cytotoxicity test.
antigen H-2.5 is accompanied by redistribution of not only H-2.23 (the Kregion
private antigen) but also of H-2.32 (the Dregion private antigen) . Surprisingly,
treatment of CBA/J cells with anti-H-2.23, but not with anti-H-2.32, abolished
the reactivity ofthese cells with H-2.5 antibodies.Thus, it appearsthatthe H-2.5
antibodies are capable of redistributing both K and D molecules but mediate
complement-dependent cytotoxicity reactions only when combined with K
molecules.
H-2.6.
￿
This is one of the least studied and least defined of the first 33 H-2
antigens. We were able to produce an antiserum (K-35) whose reactivity pattern
approaches that of anti-H-2.6. In C57BL/6(H-2°) cells, the antigen detected by
this antiserum redistributed together with H-2.33, the private antigen controlled
by the Kregion of the H-2° haplotype (Table IV). The D° region private antigen
(H-2.2) redistributed independently of both H-2.6 and H-2.33. The physical
association in the cell membrane ofantigens H-2.6and 33contradicts the genetic
mapping of antigen H-2.6 into the D region. This discrepancy between genetic
and topological mapping of H-2.6 means either that our antiserum detects a
different antigen, or that there areH-2.6sites on both Kand D molecules and our
antiserum reacts with only one of them.
H-2.8.
￿
Genetic mapping suggests that the determinant for antigen H-2.8is at
the K end and the results of our redistribution experiments (Table V) confirm
this conclusion. In B10.D2(H-2d) cells, redistribution of antigen H-2.8 was
accompanied by the redistribution of the Kend antigen H-2.31, and vice versa,
whereas, the D end antigen H-2.4 redistributed independently of the two.
K-2.11.
￿
Redistribution of antigen H-2.11 in DBA/1J(H-2Q) cells was always
accompanied by the redistribution of K region antigen H-2.17, and vice versa,
Treated with
As*
Tested with
As
1 :2
Dead cells at As dilution$
1 :4 1 :8 1:16 1:32
- D-lb 85 80 70 60 35
D-lb(n) D-lb 12 10 8 10 15
K-304(n) D-lb 70 55 35 30 25
K-323(n) D-lb 12 10 12 10 10
- K-304 95 95 92 65 30
K-304(n) K-304 12 12 12 12 12
D-lb(n) K-304 95 95 75 60 30
K-323(n) K-304 95 95 92 60 45
- K-323 100 100 90 80 75
K-323(n) K-323 12 12 12 15 12
D-lb(n) K-323 12 15 15 12 12
K-304(n) K-323 90 90 60 40 35
GAMIG NMS 8 8 5 8 5292
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TABLE III
Redistribution of Antigens H-2.5(K-46), H-2.23(K-323), and H-2.32(As-485) After Pre-
treatment of CBAIJ(H-2k) Spleen Cells with H-2 Alloantisera and GAMIG
* As = H-2 alloantiserum; dilution of antiserum in parentheses; n = undiluted.
$Measured in cytotoxicity test.
TABLE IV
Redistribution of Antigens H-2.6(K-35), H-2.33(K-30), and H-2.2(K-302) After Pretreat-
ment of C57BL/6(H-2°) Spleen Cells with H-2 Alloantisera and GAMIG
* As = H-2 alloantiserum; dilution of antiserum in parentheses; n = undiluted.
$Measured in cytotoxicity test.
whereas redistribution of D region antigen H-2.30 did not change the distribution
of H-2.11 (Table VI). This result is in agreement with genetic mapping placing
the determinant for antigen H-2.11 in the K region.
H-2.13. Tests with antigen H-2.13 inconclusively suggested association of
Treated with
As*
Tested with
As 1:2
Dead cells at As dilution$
1:4 1 :8 1:16 1 :32
- K-46 80 75 35 12 8
K-46(n) K-46 20 20 18 18 18
K-323(n) K-46 12 10 10 10 10
As-485(1:16) K-46 80 70 40 12 12
- K-323 95 95 82 60 35
K-323(n) K-323 10 10 12 10 10
K-46(n) K-323 25 28 25 25 25
As-485(1 :16) K-323 85 80 70 50 20
- As-485 90 90 90 88 75
As-485(1 :16) As-485 12 15 12 12 10
K-46(n) As-485 30 35 20 30 30
K-323(n) As-485 85 80 80 70 68
GAMIG NMS 12 12 15 12 15
Treated with
As*
Tested with
As
1 :2
Dead cells at As dilution$
1 :4 1 :8 1:16 1:32
- K-35 70 70 42 10 8
K-35(n) K-35 25 20 18 15 15
K-30(n) K-35 40 35 15 12 12
K-302(n) K-35 85 75 35 12 12
- K-30 100 100 95 80 35
K-30(n) K-30 15 18 15 10 10
K-35(n) K-30 55 38 28 22 12
K-302(n) K-30 95 95 88 60 20
- K-302 95 90 50 22 10
K-302(n) K-302 10 10 10 10 10
K-35(n) K-302 75 72 65 60 28
K-30(n) K-302 80 80 70 65 25
GAMIG NMS 10 10 10 10 10this antigen in DBA/1J(H-2Q) cells with the D region antigen H-2.30 and
independence from K region antigen H-2.17 (Table VII). Cells treated with
anti-H-2.13 (D-13) became resistant to subsequent action of anti-H-2.30 (K-113)
while remaining susceptible to the action of anti-H-2.17(K-26). However,
TABLE V
Redistribution of Antigens H-2.8(D-8), H-2.31(K-131), and H-2.4(K-340) AfterPretreat-
ment of BIO.D2(H-2d) Spleen Cells with H-2 Alloantisera and GAMIG
V
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* As = H-2 alloantiserum ; dilution of antiserum in parentheses; n = undiluted.
$ Measured in cytotoxicity test .
TABLE VI
Redistribution of Antigens H-231(C-11A), H-2.17(K-26), and H-2.30(K-113) After
Pretreatment of DBAIIJ(H-2Q) Spleen Cells with H-2 Alloantisera and GAMIG
* As = H-2alloantiserum ; dilution of antiserum in parentheses; n = undiluted.
$ Measured in cytotoxicity test.
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Treated with
As*
Tested with
As
1:2
Dead cells at As dilution$
1:4 1:8 1:16 1:32
D-8 90 80 65 50 38
D-8(n) D-8 30 22 18 20 20
K-131(n) D-8 30 38 25 22 20
K-304(n) D-8 85 80 65 60 50
K-131 95 88 85 70 60
K-131(n) K-131 35 35 20 35 28
D-8(n) K-131 58 60 60 45 40
K-304(n) K-131 85 80 75 60 50
K-304 95 95 90 80 60
K-304(n) K-304 38 35 25 25 28
D-8(n) K-304 90 90 85 75 60
K-131(n) K-304 90 90 85 80 80
GAMIG NMS 15 20 20 15 20
Treated with
As*
Tested with
As
1:2
Dead cells at As dilution$
1:4 1:8 1:16 1:32
C-11A 95 90 80 50 35
C-11A(n) C-11A 38 35 38 38 40
K-26(n) C-11A 35 35 32 35 40
K-113(n) C-11A 95 90 80 70 40
K-26 95 95 90 90 88
K-26(n) K-26 22 25 22 25 22
C-11A(n) K-26 30 35 35 35 30
K-113(n) K-26 95 90 90 88 85
K-113 95 92 85 70 55
K-113(n) K-113 50 50 40 38 40
C-11A(n) K-113 90 88 85 78 70
K-26(n) K-113 95 92 88 80 65
GAMIG NMS 38 35 40 30 15294
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TABLE VII
Redistribution of Antigens H-2.13(D-13), H-2.17(K-26), and H-2.30(K-113) After Pre-
treatment of DBA/1(H-2°) Spleen Cells with H-2 Alloantisera and GAMIG
* As = H-2 alloantiserum dilution of antiserum in parentheses; n = undiluted.
$ Measured in cytotoxicity test.
anti-H-2.30 treatment only slightlyreduced the sensitivity ofthe DBAJIJ cells to
anti-H-2.13 serum and complement. Whether the latter result was caused by the
presenceofan additional antibody in theD-13serum could not bedetermined.
H-2.25.
￿
CBA(J(H-2k) lymphocytes treated with anti-H-2.25 serum (K-325)
became resistant not only to anti-H-2.25 but also to anti-H-2.23(K-323), while
remaining fully sensitive to anti-H-2.32 (As-485, cf. Table VIII). Similarly, the
same cells treated with anti-H-2.23 became resistant to both anti-H-2.23 and
anti-H-2.25, but not to anti-H-2.32. This result, which suggests molecular
association ofantigen H-2.25 with Kregion antigen H-2.23, is in agreementwith
genetic mapping placing the H-2.25 determinant in the Kregion .
H-2.28. Antiserum D-28 contains several H-2 antibodies . However, when
tested against HTG(H-24) cells, it should react only with antigen H-2.28.
Treatment of HTG lymphocytes with D-28 makes the cells resistant not only to
D-28, but also to K-131, an antiserum specific for Kregion antigen H-2.31 (Table
IX). Similarly, treatment with K-131 makes HTG cells resistant to both K-131
and D-28, but not to K-302. Genetic mapping of H-2.28 is somewhat ambiguous
and it has been suggested (16) that the antigen might be controlled by duplicate
sites in both the K and D regions. Our data indicate that in the membrane of
HTG cells, antigen H-2.28 is associated with K region antigen H-2.31.
Discussion
The data presented in this communication prove that in the cell membrane
public H-2 antigens 1, 5, 6, 8, 11, 13, 25, and 28 are physically associated with
molecules carrying private H-2 antigens coded for by the K or D regions. The
data, however, do not provide an insight into the nature of this association.
Theoretically, co-redistribution oftwo antigens in the membrane canoccur either
Treated with
As*
Tested with
As
1:2
Dead cells at dilution$
1:4 1:8 1:16 1:32
- D-13 100 100 100 100 92
D-13(n) D-13 65 60 40 28 20
K-113(n) D-13 65 60 55 50 40
K-26(n) D-13 100 95 95 95 90
- K-113 95 95 80 70 65
K-113(n) K-113 65 45 35 30 28
D-13(n) K-113 40 35 20 18 20
K-26(n) K-113 95 90 90 75 30
- K-26 95 95 95 90 88
K-26(n) K-26 15 15 15 15 20
D-13(n) K-26 95 95 90 90 90
K-113(n) K-26 95 95 95 92 90
GAMIG NMS 20 25 20 20 20VERA HAUPTFELD AND JAN KLEIN
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TABLE VIII
Redistribution of Antigens H-2.25(K-325), H-2.23(K-323), and H-2.32(As-485) After
Pretreatment of CBA/J(H-2k) Spleen Cells with H-2 Alloantisera and GAMIG
* As = H-2 alloantiserum; dilution of antiserum in parentheses; n = undiluted.
$ Measured in cytotoxicity test.
TABLE IX
Redistribution of Antigens H-2.28(D-28), H-2.31(K-131), and H-2.2(K-302) After Pre-
treatment of HTG(H-2g) Spleen Cells with H-2Alloantisera and GAMIG
* As = H-2 alloantiserum; dilution of antiserum in parentheses; n = undiluted.
$ Measured in cytotoxicity test.
when the two antigens are carried by the same molecule, or when the antigens are
on two different molecules associated by noncovalent bonds in a supramolecular
structure which redistributes as a unit. The distinction between the two
possibilities can be made only through isolation and serological characterization
Treated with
As*
Tested with
As
1:2
Dead cells at As dilution
1 :4 1 :8 1 :16 1 :32
- K-325 90 95 95 45 25
K-325(n) K-325 20 12 8 10 8
K-323(n) K-325 10 8 8 10 10
As-485(1:16) K-325 75 50 30 12 10
- K-323 95 90 90 55 30
K-323(n) K-323 12 10 10 8 10
K-325(n) K-323 45 30 30 15 10
As-485(1 :16) K-323 95 90 85 55 32
- As-485 95 95 95 92 90
As-485(1 :16) As-485 12 18 18 18 20
K-25(n) As-485 90 95 95 55 30
K-323(n) As-485 92 95 95 70 50
GAMIG NMS 12 10 8 8 8
Treated with
As*
Tested with
As
1:2
Dead cells at As dilution*
1:4 1 :8 1 :16 1 :32
- D-28 90 82 70 65 35
D-28(n) D-28 30 28 30 28 28
K-131(n) D-28 40 42 35 35 40
K-302(n) D-28 85 85 70 70 55
- K-131 95 95 90 88 75
K-131 (n) K-131 40 30 25 25 25
D-28(n) K-131 60 65 60 60 55
K-302(n) K-131 95 92 88 80 75
- K-302 100 95 90 60 30
K-302(n) K-302 20 20 18 18 18
D-28(n) K-302 95 92 80 60 30
K-131(n) K-302 95 95 82 55 30
GAMIG NMS 25 28 30 25 30296
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of purified H-2 molecules. Such characterization, so far, has been accomplished
for only two public H-2 antigens. Cullen and her colleagues (17) demonstrated by
differential immunoprecipitation of NP-40 solubilized membrane preparation
that antigen H-2.3was on the same fragment as antigen H-2.4, and that antigen
H-2.5 was on the same fragment as antigen H-2.32. By inference, this data
strongly suggest that the associations which we observed between public and
private H-2antigens are also caused bythe twotypes of antigens being presenton
the same molecule .
Taken together with the biochemical data on antigen H-2.3, evidence is now
available that all the public antigens previously assigned to separate regions of
the H-2 complex are associated with antigens controlled by either the Korthe D
regions, or both. In other words, the data disprove the existence of separate
regions A, C, and E, and thus substantiate the principal claim ofthe two-locus
model.
Paradoxically, it is now clear that the two-locus model in its original form is an
oversimplification . Since the proposal of the model, the following developments have
taken place that complicated the interpretation of the H-2 complex. First, a class of
antigens was discovered to be controlled by the Iregion (Ia antigen, cf. ref. 18, 19), which
in some respects resembles the classical H-2 antigens, but the two classesdiffer in several
characteristics (e.g., tissue distribution and molecular weight). It is likely that the H-2
and Ia antigens are related genetically and functionally. Second, in addition to the two
strong histocompatibility loci positioned in the KandDregions, a third strong Hlocushas
recently been discovered in the I region, close to H-2K (20) . Furthermore, some
unpublished data suggest that loci coding for weak transplantation antigens might be
dispersed throughout the entire H-2 complex. Third, one of the public H-2 antigens
(H-2.7) originally believed to be controlled by the Kor Dregions was demonstrated to be
controlled by a separate region (G), located between S and D (8, 9) .
Thus, the picture ofthe H-2 complex emergingfrom current studies is that ofa
large series of loci, most likely related in their function, and displaying
considerable homology, but also some significant differences. In this array ofloci,
the two loci of the original two-locus model (H-2K and H-2D) still stand out as
the most homologous. A direct support for the homology ofthe H-2K and H-2D
loci is provided by our results on redistribution of antigen H-2.5 . We observed
that in H-2'p cells, redistribution of antigen H-2.5 is accompanied by redistribu-
tion of both K (H-2.23) and D (H-2.32) region private antigens. This observation
is first direct evidence for the validity of the duplication model of H-2.
The data presented in this communication also demonstrate that the tech-
nique of AMIRC is a powerful tool for evaluation of topological relationships
among antigens in the cell membrane . In the absence of reliable biochemical
data, it could provide the missing link between serology andgenetics in the study
of a complex antigenic system .
Summary
Molecular relationship of public H-2 antigens 1, 5, 6, 8, 11, 13, 25, and 28 to
private antigens controlled by Kand Dregions was studied using the technique
of antibody-induced resistance to complement-mediated cytotoxicity. The re-
sults indicate physical association in the cell membrane between H-2 antigens 1and 23 of H-2a, 8 and 31 of H-2d, 11 and 17 of H-2Q, 13 and 30 ofH-2", 25 and 23 of
H-2k, and 28 and 31 ofH-2g. These results are in agreement with genetic mapping
placing the determinants of antigens H-2.8, 11, and 25 in the K region, the
determinant of antigen H-2.13 in the D region, and the determinants of antigens
H-2.1 and 28 in either the K or the D region. In contrast to genetic mapping
placing the determinant for antigen H-2.6 in the D region, we found that in the
H-2° haplotype the antigen is associated with K region antigen H-2.33. We found
antigen H-2.5 in the H-2'p associated with both H-2.33 and H-2.32, and
interpreted this result as evidence for two homologous H-2.5 sites controlled by
opposite ends of the H-2 complex. Although the data do not prove that public
antigens are carried by the same molecules as private ones, they demonstrate a
close physical association in the membrane between the two groups of antigens.
The data provide strong experimental evidence that there are two groups of loci,
K and D, coding for the first 33 classical H-2 antigens (with the exception of
antigen H-2.7), and thus support the two-locus model. The data also support the
duplication model of H-2 by demonstrating two homologous H-2.5 sites associ-
ated with K and D molecules .
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